PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
(Thomson Reuters ONE) -
REGULATED INFORMATION
GHENT, Belgium, 14 March 2016 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY]
today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007
regarding the publication of major shareholdings in issuers whose securities are
admitted to trading on a regulated market (the "Transparency Law"), that it
received a notification of shareholdings from Aviva plc and Aviva Investors
Global Services Limited.
The above shareholders have notified Ablynx that they have dropped below the 3%
threshold and now hold 901,029 Ablynx shares, which represent 1.64% of the
current 55,108,065 outstanding Ablynx shares.
The voting rights are managed and controlled by Aviva Investors Global Services
Limited, with the following chain of controlled undertakings: Aviva plc (Parent
Company), Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc),
Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group
Holdings Limited), Aviva Investors Global Services Limited (wholly owned
subsidiary of Aviva Investors Holdings Limited).
Full versions of all transparency notifications are available on Ablynx website,
under the section Investors.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®,
proprietary therapeutic proteins based on single-domain antibody fragments,
which combine the advantages of conventional antibody drugs with some of the
features of small-molecule drugs. Ablynx is dedicated to creating new medicines
which will make a real difference to society. Today, the Company has more than
40 proprietary and partnered programmes in development in various therapeutic
areas including inflammation, haematology, immuno-oncology, oncology and
respiratory disease. The Company has collaborations with multiple pharmaceutical
companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck &
Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceutical Co.,
Ltd. The Company is headquartered in Ghent, Belgium. More information can be
found on www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses(at)ablynx.com
Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch(at)ablynx.com
Follow us on Twitter (at)AblynxABLX
Ablynx media relations Instinctif Partners:
Sue Charles, Daniel Gooch
London office
t: +44 (0)20 7866 7905
e: ablynx(at)instinctif.com
Belgium/Dutch and French language
Jim Rusagara
Brussels office
t: +32 (0)2 626 9500
e: ablynx(at)instinctif.com
pdf format of the press release:
http://hugin.info/137912/R/1993813/734103.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Ablynx via GlobeNewswire
[HUG#1993813]
Unternehmensinformation / Kurzprofil:
Datum: 14.03.2016 - 07:00 Uhr
Sprache: Deutsch
News-ID 457051
Anzahl Zeichen: 3760
contact information:
Town:
Ghent/Zwijnaarde
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 265 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
